Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remegal in refractory partial seizures
NCT01179854Phase 2Completed
- Sponsor
- Valexfarm
- Start
- Sep 2009
- Primary completion
- Nov 2010
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Remegal in Focal epilepsy (FE) (4 arms), sponsored by Valexfarm. Primary endpoint: Safety and tolerability at 12 months. Started Sep 2009; status: completed.
02
Drugs
Remegal
03
Conditions
Focal epilepsy (FE)
Beyond the preview
Go deeper on NCT01179854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01179854.